Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
- PMID: 9360926
- DOI: 10.1126/science.278.5341.1291
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
Abstract
In evaluating current combination drug regimens for treatment of human immunodeficiency virus (HIV) disease, it is important to determine the existence of viral reservoirs. After depletion of CD8 cells from the peripheral blood mononuclear cells (PBMCs) of both patients and normal donors, activation of patient CD4 lymphocytes with immobilized antibodies to CD3 and CD28 enabled the isolation of virus from PBMCs of six patients despite the suppression of their plasma HIV RNA to fewer than 50 copies per milliliter for up to 2 years. Partial sequencing of HIV pol revealed no new drug resistance mutations or discernible evolution, providing evidence for viral latency rather than drug failure.
Comment in
-
HIV survives drug onslaught by hiding out in T cells.Science. 1997 Nov 14;278(5341):1227. doi: 10.1126/science.278.5341.1227. Science. 1997. PMID: 9411749 No abstract available.
Similar articles
-
Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.J Infect Dis. 1999 Aug;180(2):320-9. doi: 10.1086/314880. J Infect Dis. 1999. PMID: 10395845 Clinical Trial.
-
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.N Engl J Med. 1998 Oct 29;339(18):1261-8. doi: 10.1056/NEJM199810293391801. N Engl J Med. 1998. PMID: 9791141 Clinical Trial.
-
Prevalence and predictive value of intermittent viremia with combination hiv therapy.JAMA. 2001 Jul 11;286(2):171-9. doi: 10.1001/jama.286.2.171. JAMA. 2001. PMID: 11448280
-
Measuring HIV Persistence on Antiretroviral Therapy.Adv Exp Med Biol. 2018;1075:265-284. doi: 10.1007/978-981-13-0484-2_11. Adv Exp Med Biol. 2018. PMID: 30030797 Review.
-
Can HIV infection be eradicated through use of potent antiviral agents?Curr Opin Infect Dis. 2010 Dec;23(6):628-32. doi: 10.1097/QCO.0b013e32833ff1d0. Curr Opin Infect Dis. 2010. PMID: 20847693 Review.
Cited by
-
Impact of viral activators and epigenetic regulators on HIV-1 LTRs containing naturally occurring single nucleotide polymorphisms.Biomed Res Int. 2015;2015:320642. doi: 10.1155/2015/320642. Epub 2015 Jan 5. Biomed Res Int. 2015. PMID: 25629043 Free PMC article.
-
Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency.Mol Ther. 2016 Sep;24(9):1528-37. doi: 10.1038/mt.2016.117. Epub 2016 Jun 6. Mol Ther. 2016. PMID: 27434587 Free PMC article.
-
In Situ Detection of Endogenous HIV Activation by Dynamic Nuclear Polarization NMR and Flow Cytometry.Int J Mol Sci. 2020 Jun 30;21(13):4649. doi: 10.3390/ijms21134649. Int J Mol Sci. 2020. PMID: 32629894 Free PMC article.
-
Machine learning approaches identify immunologic signatures of total and intact HIV DNA during long-term antiretroviral therapy.Elife. 2024 Sep 9;13:RP94899. doi: 10.7554/eLife.94899. Elife. 2024. PMID: 39250423 Free PMC article.
-
Modulation of Antiviral Immunity and Therapeutic Efficacy by 25-Hydroxycholesterol in Chronically SIV-Infected, ART-Treated Rhesus Macaques.Virol Sin. 2021 Oct;36(5):1197-1209. doi: 10.1007/s12250-021-00407-6. Epub 2021 May 31. Virol Sin. 2021. PMID: 34057681 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials